Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T04:44:18.816Z Has data issue: false hasContentIssue false

Antipsychotics in Pregnancy

Published online by Cambridge University Press:  15 April 2020

T. Carvalhão
Affiliation:
Psychiatry, Hospitais da Universidade de Coimbra, Coimbra, Portugal Psychiatry Hospitais da Universidade de Coimbra, Coimbra, Portugal
T. Silva
Affiliation:
Psychiatry, Hospitais da Universidade de Coimbra, Coimbra, Portugal Psychiatry Hospitais da Universidade de Coimbra, Coimbra, Portugal
M.J. Piçarra
Affiliation:
Psychiatry, Hospitais da Universidade de Coimbra, Coimbra, Portugal Psychiatry Hospitais da Universidade de Coimbra, Coimbra, Portugal
G. Santos
Affiliation:
Psychiatry, Hospitais da Universidade de Coimbra, Coimbra, Portugal Psychiatry Hospitais da Universidade de Coimbra, Coimbra, Portugal

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The fear of deleterious effects of psychotic drugs on the fetus is a major concern for women who need this therapy, damaging the medication adherence at the time of pregnancy.

The non-adherence to therapy can take to disease recurrence which will bring additional risks for the pregnancy and the postpartum. So, it is extremely important to evaluate the psychotic drugs safety during pregnancy.

Purpose

Literature review on the use of anitpsychotic drugs during pregnancy.

Methodology

Literature review of the subject, using available database in the Central Library of CHUC

Results

All the antipsychotic drugs cross the placenta and the fetus is always exposed to these. When choosing the antipsychotic drug, the possible morphological teratogenesis must be taken into account, particularly between the third and the eighth week of pregnancy.

The typical antipsychotic drugs do not seem to bring a significant risk of malformations and the antipsychotic drugs with sedative properties can represent an increased risk of non-specific teratogenic effects during the first three months of pregnancy.

In the pregnant woman the atypical antipsychotic drugs cause weight gain, hyperglycemia and dyslipedemia. These disturbances are associated with the considerable risk increase of fetal complications.

Conclusions

No drug is considered completely safe and no antipsychotic drug was approved to be used during pregnancy or breastfeeding by the Food Drug Administration.

Though there is no clear evidence of malformations risk, there is evidence of risks related with the pregnancy and the neonatal period.

Type
Article: 1936
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.